Biotech failure, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Elmer who wrote (47)	4/15/2002 8:30:55 PM
From: Miljenko Zuanic	of 130

Reuters Business Human Genome ends work on one drug, looks at another ROCKVILLE, Md., April 15 (Reuters) - Biotechnology firm Human Genome Sciences Inc. (NasdaqNM:HGSI - news) on Monday said it has discontinued development of Mirostipen as a single, stand-alone agent for the treatment of a decrease in white blood cells caused by chemotherapy. Instead, the Rockville, Maryland-based company said it has embarked on a new initiative to develop a long-acting form of Granulocyte Colony Stimulating Factor (G-CSF) for treatment of the same disorder, known as neutropenia. The new drug, Albugranin, was made using Human Genome Sciences' proprietary albumin fusion technology. Human Genome said it expects to file an investigational new drug application with the U.S. Food and Drug Administration ``within the next several weeks'' for Albugranin

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next